Yaqrit

Executive Summary

Yaqrit Discovery Ltd is a UK-based biotechnology company dedicated to developing life-saving treatments for patients with advanced liver disease. Founded in 2013, the company leverages a deep understanding of inflammation and the body's response to liver injury to target multiple stages of disease progression. Its pipeline includes novel therapeutics and devices addressing conditions such as hepatic encephalopathy, acute-on-chronic liver failure (ACLF), and primary sclerosing cholangitis (PSC). By focusing on unmet medical needs in hepatology, Yaqrit aims to improve outcomes for patients with limited therapeutic options. The company's integrated approach positions it to potentially address critical gaps in the management of advanced liver diseases, which are a growing global health burden.

Upcoming Catalysts (preview)

• Q3 2026Phase 2a data readout for lead ACLF candidate60% success
• TBDRegulatory meeting (EOP2) for PSC program70% success
• TBDPotential partnership or licensing deal for hepatic encephalopathy device50% success